


ONXEO SA

- ✓ Founded in 1997, Onxeo designs and develops innovative medicines for the treatment of rare and resistant cancers.
- ✓ The Company develops, through patented and original technologies, drugs that act specifically on tumor DNA repair mechanisms.



- 1** Several DNA repair avenues are activated in cancer cells via the recruitment of enzymes enabling them to efficiently repair their damaged DNA and avoid cell death;
- 2** AsiDNA™ mimics a DNA break in the cancer cells and activates the enzyme signaling DNA damage, thus inducing a false damage signal preventing repair enzymes from being recruited on the site where they should act in order to repair damage on the tumor cell's chromosomes;
- 3** Cancer cells are no longer able to divide with damaged DNA, which ultimately leads to cell death.

- **EQUITY LINE de € 5.4M/12 months**
- *Revenues 2018 : 6,1M Euro*
- *Market Cap: 50M Euro*
- At December 31, 2018, the company had consolidated cash of € 11.3 million compared to € 14.3 million at December 31, 2017. This cash level includes € 2.7 million of gross proceeds from the use of the equity financing line set up with Nice & Green SA.
- Full utilization of this financial reserve will allow the company to achieve short-term value-creating milestones as a result of ongoing preclinical and clinical programs.

